Massachusetts General Hospital

Juniper Pharmaceuticals formation scientific advisory board

Friday, April 24, 2015 01:52 PM

Juniper Pharmaceuticals, a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health, has created a scientific advisory board (SAB) comprised of international physicians and scientists whose mission will be to provide scientific and clinical advice on the identification and advancement of product candidates for Juniper's women's health portfolio.

More... »

Quest Diagnostics

ALS Association, Harvard, Massachusetts General collaborate with GSK

Friday, April 17, 2015 12:56 PM

The ALS AssociationHarvard Stem Cell Institute and Massachusetts General Hospital Neurological Clinical Research Institute are collaborating with GlaxoSmithKline on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. In parallel testing, brain cells will be made from each patient's stem cells to see if they can predict which patients might respond to the medicine.

More... »


NIH forms team to chart course for Precision Medicine Initiative research network

Wednesday, April 1, 2015 01:08 PM

A newly created team of experts in precision medicine and large clinical research studies will seek public input from the large and diverse stakeholder community interested in the development of the President’s Precision Medicine Initiative and articulate the vision for building the national participant group for the Initiative. They will help define what can be learned from a study of this scale and scope, what issues will need to be addressed and considered as part of the study design and what success would look like five and 10 years out.

More... »

NIH awards $9M to speed development of health technologies

Monday, March 30, 2015 02:13 PM

The NIH has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded $9 million over three years.

More... »

The Medicines Company acquires Annovation Biopharma

Thursday, February 5, 2015 12:08 PM

The Medicines Company has completed its acquisition of all of the outstanding equity of Annovation Biopharma, a company focused on creating more effective, safer therapies for anesthesia and critical care. Based on technology licensed from Massachusetts General Hospital, Annovation is developing ABP-700, a novel intravenous anesthetic which in phase I clinical studies has demonstrated potent and rapidly reversible anesthetic effects.

More... »

Infraredx, Massachusetts General Hospital collaborate on cardiovascular imaging devices

Wednesday, December 17, 2014 12:26 PM

Infraredx, a Burlington, Mass.-based cardiovascular imaging company, is collaborating with Massachusetts General Hospital (MGH) and coronary imaging researcher Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.

More... »

ALS Association awards research funds for C9orf72 clinical trials

Friday, December 12, 2014 03:34 PM

The ALS Association, a national nonprofit organization based in Wash. D.C., has awarded $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene.

More... »

NIH launches Illuminating the Druggable Genome to find potential drug targets

Wednesday, October 29, 2014 01:09 PM

NIH has announced a new collaborative initiative to improve human health by exploring poorly understood genes that have the potential to be modified by medicines. The effort is part of an NIH Common Fund three-year pilot project called Illuminating the Druggable Genome (IDG). For the initial phase of the program, NIH has allocated $5.8 million to eight institutions and for intramural resources.

More... »

Center for Connected Health, Daiichi Sankyo ink mobile app agreement

Thursday, October 23, 2014 01:19 PM

The Center for Connected Health, a division of Partners HealthCare, a Boston-based healthcare delivery system founded by Harvard Medical School affiliated teaching institutions Brigham and Women's Hospital and Massachusetts General Hospital, has announced a co-development agreement with Japanese pharmaceutical Daiichi Sankyo to create a mobile app to serve as a coaching platform for patients with atrial fibrillation who have been prescribed oral anticoagulation therapy.

More... »

PPD acquires RCT Logic's exclusive license to clinical trial design technology

Monday, September 8, 2014 01:50 PM

Pharmaceutical Product Development (PPD), a Wilmington, N.C.-based CRO, has acquired RCT Logic's exclusive license from Massachusetts General Hospital (MGH) for the portfolio of patents related to its sequential parallel comparison design (SPCD).

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs